Spinocerebellar Ataxia
Conditions
Interventions
This is a single-blind clinical trial, in which participants will be informed and will need to agree and sign that they may receive placebo medication or pure cannabidiol extract, but all will receive
Sponsors
Universidade Federal do Paraná
Universidade Federal do Paraná
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients from the Movement Disorders Outpatient Clinic of the Neurology Service of the Hospital de Clínicas - UFPR (HC - UFPR) over 18 years old who already had the genetic diagnosis of spinocerebellar ataxia type 10 (SCA10); patients who agreed and signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: Patients who did not agree with the Informed Consent Form; patients who did not have a genetic diagnosis of SCA10; demented patients; and patients who did not use the intervention correctly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find improvement in the clinical evaluation of patients through observation and verification of the decrease in the score of the SARA scale (Scale for the Assessment and Rating of Ataxia) proven by ANOVA statistical analysis of repeated measures comparing the mean score of patients on the SARA scale on study day 0 (before intervention use) and on study day 30 (after one month of intervention use). | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to observe the safety and tolerability of the intervention through the observation and report of its adverse effects cited by the patients themselves. | — |
Countries
Brazil
Contacts
Public ContactBárbara Luiza;Ana Chrystina Afonso;Crippa
Universidade Federal do Paraná;Universidade Federal do Paraná
Outcome results
None listed